Update on the Evolving Landscape for Endometrial Cancer Treatment with Immunotherapy

ON DEMAND LAUNCH:

22 September 2020 9.00 CET
Co-chairs: Robert Coleman, MD, FACOG, FACS, and Ana Oaknin, MD, PhD

Please join our expert Faculty for a 90-minute virtual symposium that will be available on demand 22-29 September. The symposium will provide an overview of the use of biomarkers to help guide treatment decisions and the role of immunotherapy in treating endometrial cancer.

Symposium Objectives

• To explore the evolution of diagnosis and characterization of endometrial cancer and the emergence of mismatch repair as a biomarker
• To review the rationale for evaluation of checkpoint inhibitors in the treatment of recurrent endometrial cancer
• To review current and upcoming clinical data on the role of immunotherapy in endometrial cancer
• To understand the patient journey for endometrial cancer patients

Please join our expert Faculty for a 30-minute live Q&A: 24 September 2020 15.30-16.00 CET

Faculty

Robert Coleman, MD, FACOG, FACS
(Co-chair):
The US Oncology Network,
The Woodlands, TX, USA

Ana Oaknin, MD, PhD
(Co-chair):
Vall d’Hebrón University Hospital,
Vall d’Hebrón Institute of Oncology (VHIO),
Barcelona, Spain

Amit M. Oza, BSc, MD, MBBS, FRCPC
Professor of Medicine, University of Toronto
Head, Division of Medical Oncology & Hematology
Princess Margaret Cancer Centre,
University Health Network & Sinai Health System
Toronto, Canada

Renaud Sabatier, MD PhD
Department of Medical Oncology
Institut Paoli-Calmettes
Marseille, France

Supported by

This material was developed in compliance with the EFPIA code.
©2020 GSK group of companies or its licensor. All rights reserved. SE-GBL-DST-PPT-200014. August 2020.